Outcomes in COVID-19 nitazoxanide studies
0
0.5
1
1.5+
All studies 33% 13
3,606
Improvement, Studies, Patients Relative Risk Mortality 42% 6
1,877
Ventilation 82% 3
588
ICU admission 28% 3
841
Hospitalization 61% 6
1,864
Progression -120% 2
981
Recovery 1% 5
1,309
Cases 17% 1
505
Viral clearance 38% 7
865
RCTs 8% 10
2,955
RCT mortality 28% 4
1,339
Peer-reviewed 54% 10
2,608
Prophylaxis 66% 1
505
Early 29% 8
2,545
Late 12% 4
556
Nitazoxanide for COVID-19 c19 early.org/n Dec 2022Favors nitazoxanide Favors control after exclusions
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI] Treatment Control Cadegiani 88%
0.12 [0.01-2.52]
death
0/357
2/137
Elalfy 87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT2
Silva (SB RCT) 26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Rossignol (DB RCT) -206%
3.06 [0.13-74.6]
death
1/184
0/195
ANTICOV (RCT) -188%
2.88 [1.05-7.85]
progression
15/462
5/443
OT1 CT2
Medhat (RCT) 56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Chandiwana (RCT) -13%
1.13 [0.23-5.46]
progression
37 (n)
39 (n)
CT2
Tau2 = 1.04, I2 = 78.3%, p = 0.46
Early treatment 29%
0.71 [0.29-1.73]
25/1,396
51/1,149
29% improvement Blum (DB RCT) 67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI] Treatment Control Calderón 68%
0.32 [0.04-2.49]
death
1/17
5/27
OT1
Fowotade (RCT) -11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT2
Rocco (DB RCT) -5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau2 = 0.03, I2 = 7.9%, p = 0.65
Late treatment 12%
0.88 [0.52-1.50]
9/275
16/281
12% improvement Sokhela (RCT) 66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.52
Prophylaxis 66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement All studies 33%
0.67 [0.37-1.22]
34/1,911
68/1,695
33% improvement 13 nitazoxanide COVID-19 studies c19 early.org/n Dec 2022Tau2 = 0.66, I2 = 69.4%, p = 0.19
Effect extraction pre-specified (most serious outcome) 1 OT: comparison with other treatment 2 CT: study uses combined treatment Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI] Treatment Control Cadegiani 88%
0.12 [0.01-2.52]
death
0/357
2/137
Elalfy 87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT2
Silva (SB RCT) 26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Rossignol (DB RCT) -206%
3.06 [0.13-74.6]
death
1/184
0/195
Medhat (RCT) 56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Chandiwana (RCT) -13%
1.13 [0.23-5.46]
progression
37 (n)
39 (n)
CT2
Tau2 = 0.67, I2 = 69.3%, p = 0.12
Early treatment 49%
0.51 [0.22-1.18]
10/934
46/706
49% improvement Blum (DB RCT) 67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI] Treatment Control Calderón 68%
0.32 [0.04-2.49]
death
1/17
5/27
OT1
Fowotade (RCT) -11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT2
Rocco (DB RCT) -5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau2 = 0.03, I2 = 7.9%, p = 0.65
Late treatment 12%
0.88 [0.52-1.50]
9/275
16/281
12% improvement Sokhela (RCT) 66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.52
Prophylaxis 66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement All studies 44%
0.56 [0.32-1.01]
19/1,449
63/1,252
44% improvement 12 nitazoxanide COVID-19 studies after exclusions c19 early.org/n Dec 2022Tau2 = 0.50, I2 = 63.0%, p = 0.052
Effect extraction pre-specified (most serious outcome) 1 OT: comparison with other treatment 2 CT: study uses combined treatment Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani 88%
0.12 [0.01-2.52]
0/357
2/137
Improvement, RR [CI] Treatment Control Rossignol (DB RCT) -206%
3.06 [0.13-74.6]
1/184
0/195
Tau2 = 2.67, I2 = 51.4%, p = 0.75
Early treatment 41%
0.59 [0.02-13.8]
1/541
2/332
41% improvement Blum (DB RCT) 67%
0.33 [0.07-1.50]
2/25
6/25
Improvement, RR [CI] Treatment Control Calderón 68%
0.32 [0.04-2.49]
1/17
5/27
OT1
Rocco (DB RCT) -5%
1.05 [0.30-3.50]
6/202
5/203
Tau2 = 0.00, I2 = 0.0%, p = 0.23
Late treatment 40%
0.60 [0.26-1.39]
9/244
16/255
40% improvement Sokhela (RCT) 66%
0.34 [0.01-8.41]
0/240
1/265
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.52
Prophylaxis 66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement All studies 42%
0.58 [0.27-1.24]
10/1,025
19/852
42% improvement 6 nitazoxanide COVID-19 mortality results c19 early.org/n Dec 2022Tau2 = 0.00, I2 = 0.0%, p = 0.16
1 OT: comparison with other treatment Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani 97%
0.03 [0.00-0.51]
0/357
9/137
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.015
Early treatment 97%
0.03 [0.00-0.51]
0/357
9/137
97% improvement Blum (DB RCT) 62%
0.38 [0.11-1.25]
3/25
8/25
Improvement, RR [CI] Treatment Control Calderón 87%
0.13 [0.01-2.33]
0/17
4/27
OT1
Tau2 = 0.00, I2 = 0.0%, p = 0.044
Late treatment 68%
0.32 [0.11-0.97]
3/42
12/52
68% improvement All studies 82%
0.18 [0.04-0.76]
3/399
21/189
82% improvement 3 nitazoxanide COVID-19 mechanical ventilation results c19 early.org/n Dec 2022Tau2 = 0.50, I2 = 27.5%, p = 0.019
1 OT: comparison with other treatment Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -404%
5.04 [0.24-104]
2/194
0/198
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.3
Early treatment -404%
5.04 [0.24-104]
2/194
0/198
-404% improvement Calderón 59%
0.41 [0.25-0.59]
0/17
16/27
OT1
Improvement, RR [CI] Treatment Control Rocco (DB RCT) 31%
0.69 [0.40-1.17]
20/202
30/203
Tau2 = 0.00, I2 = 0.0%, p = 0.15
Late treatment 32%
0.68 [0.40-1.15]
20/219
46/230
32% improvement All studies 28%
0.72 [0.43-1.21]
22/413
46/428
28% improvement 3 nitazoxanide COVID-19 ICU results c19 early.org/n Dec 2022Tau2 = 0.00, I2 = 0.0%, p = 0.22
1 OT: comparison with other treatment Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -2%
1.02 [0.30-3.47]
hosp.
5/194
5/198
Improvement, RR [CI] Treatment Control Cadegiani 99%
0.01 [0.00-0.17]
hosp.
0/357
27/137
Rossignol (DB RCT) 79%
0.21 [0.02-1.80]
hosp.
1/184
5/195
Tau2 = 3.68, I2 = 78.4%, p = 0.16
Early treatment 83%
0.17 [0.01-2.00]
6/735
37/530
83% improvement Blum (DB RCT) 56%
0.44 [0.22-0.89]
hosp. time
25 (n)
25 (n)
Improvement, RR [CI] Treatment Control Calderón 52%
0.48 [0.29-0.82]
hosp. time
17 (n)
27 (n)
OT1
Tau2 = 0.00, I2 = 0.0%, p = 0.0004
Late treatment 53%
0.47 [0.31-0.71]
0/42
0/52
53% improvement Sokhela (RCT) 79%
0.21 [0.01-4.31]
hosp.
0/240
2/265
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.31
Prophylaxis 79%
0.21 [0.01-4.31]
0/240
2/265
79% improvement All studies 61%
0.39 [0.20-0.78]
6/1,017
39/847
61% improvement 6 nitazoxanide COVID-19 hospitalization results c19 early.org/n Dec 2022Tau2 = 0.29, I2 = 47.9%, p = 0.0078
1 OT: comparison with other treatment Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI] Treatment Control Cadegiani 88%
0.12 [0.01-2.52]
death
0/357
2/137
Rossignol (DB RCT) -206%
3.06 [0.13-74.6]
death
1/184
0/195
ANTICOV (RCT) -188%
2.88 [1.05-7.85]
progression
15/462
5/443
OT1 CT2
Chandiwana (RCT) -13%
1.13 [0.23-5.46]
progression
37 (n)
39 (n)
CT2
Tau2 = 0.18, I2 = 15.0%, p = 0.2
Early treatment -82%
1.82 [0.73-4.53]
18/1,234
7/1,012
-82% improvement Blum (DB RCT) 67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI] Treatment Control Calderón 68%
0.32 [0.04-2.49]
death
1/17
5/27
OT1
Rocco (DB RCT) -5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau2 = 0.00, I2 = 0.0%, p = 0.23
Late treatment 40%
0.60 [0.26-1.39]
9/244
16/255
40% improvement Sokhela (RCT) 66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.52
Prophylaxis 66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement All studies 2%
0.98 [0.47-2.01]
27/1,718
24/1,532
2% improvement 9 nitazoxanide COVID-19 serious outcomes c19 early.org/n Dec 2022Tau2 = 0.33, I2 = 28.9%, p = 0.95
Effect extraction pre-specified (most serious outcome) 1 OT: comparison with other treatment 2 CT: study uses combined treatment Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -16%
1.16 [0.84-1.59]
no recov.
59/194
52/198
Improvement, RR [CI] Treatment Control Rossignol (DB RCT) -7%
1.07 [0.46-2.49]
recov. time
184 (n)
195 (n)
Chandiwana (RCT) -23%
1.23 [0.73-2.08]
recov. time
37 (n)
39 (n)
CT1
Tau2 = 0.00, I2 = 0.0%, p = 0.23
Early treatment -17%
1.17 [0.91-1.51]
59/415
52/432
-17% improvement Fowotade (RCT) -11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT1
Improvement, RR [CI] Treatment Control Rocco (DB RCT) 27%
0.73 [0.58-0.90]
no disch.
202 (n)
203 (n)
Tau2 = 0.04, I2 = 45.6%, p = 0.33
Late treatment 17%
0.83 [0.57-1.21]
0/233
0/229
17% improvement All studies 1%
0.99 [0.76-1.30]
59/648
52/661
1% improvement 5 nitazoxanide COVID-19 recovery results c19 early.org/n Dec 2022Tau2 = 0.04, I2 = 51.6%, p = 0.95
1 CT: study uses combined treatment Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Sokhela (RCT) 17%
0.83 [0.50-1.40]
symp. case
23/240
37/265
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.47
Prophylaxis 17%
0.83 [0.50-1.40]
23/240
37/265
17% improvement All studies 17%
0.83 [0.51-1.36]
23/240
37/265
17% improvement 1 nitazoxanide COVID-19 case result c19 early.org/n Dec 2022Tau2 = 0.00, I2 = 0.0%, p = 0.47
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) 12%
0.88 [0.80-0.96]
viral+
194 (n)
198 (n)
Improvement, RR [CI] Treatment Control Elalfy 87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT1
Silva (SB RCT) 26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Medhat (RCT) 56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Chandiwana (RCT) -67%
1.67 [0.85-3.23]
viral+
27/37
25/38
CT1
Tau2 = 0.37, I2 = 91.9%, p = 0.11
Early treatment 38%
0.62 [0.35-1.11]
34/393
69/373
38% improvement Blum (DB RCT) 90%
0.10 [0.01-1.78]
viral+
0/23
4/19
Improvement, RR [CI] Treatment Control Fowotade (RCT) 5%
0.95 [0.34-2.64]
viral load
31 (n)
26 (n)
CT1
Tau2 = 1.31, I2 = 52.6%, p = 0.48
Late treatment 53%
0.47 [0.06-3.59]
0/54
4/45
53% improvement All studies 38%
0.62 [0.37-1.05]
34/447
73/418
38% improvement 7 nitazoxanide COVID-19 viral clearance results c19 early.org/n Dec 2022Tau2 = 0.35, I2 = 88.3%, p = 0.076
1 CT: study uses combined treatment Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI] Treatment Control Silva (SB RCT) 26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Rossignol (DB RCT) -206%
3.06 [0.13-74.6]
death
1/184
0/195
ANTICOV (RCT) -188%
2.88 [1.05-7.85]
progression
15/462
5/443
OT1 CT2
Medhat (RCT) 56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Chandiwana (RCT) -13%
1.13 [0.23-5.46]
progression
37 (n)
39 (n)
CT2
Tau2 = 0.39, I2 = 56.0%, p = 0.87
Early treatment -7%
1.07 [0.51-2.23]
18/977
5/961
-7% improvement Blum (DB RCT) 67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI] Treatment Control Fowotade (RCT) -11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT2
Rocco (DB RCT) -5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau2 = 0.03, I2 = 8.5%, p = 0.86
Late treatment 5%
0.95 [0.55-1.63]
8/258
11/254
5% improvement Sokhela (RCT) 66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.52
Prophylaxis 66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement All studies 8%
0.92 [0.59-1.43]
26/1,475
17/1,480
8% improvement 10 nitazoxanide COVID-19 Randomized Controlled Trials c19 early.org/n Dec 2022Tau2 = 0.16, I2 = 36.1%, p = 0.72
Effect extraction pre-specified (most serious outcome) 1 OT: comparison with other treatment 2 CT: study uses combined treatment Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rossignol (DB RCT) -206%
3.06 [0.13-74.6]
1/184
0/195
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.5
Early treatment -206%
3.06 [0.13-74.6]
1/184
0/195
-206% improvement Blum (DB RCT) 67%
0.33 [0.07-1.50]
2/25
6/25
Improvement, RR [CI] Treatment Control Rocco (DB RCT) -5%
1.05 [0.30-3.50]
6/202
5/203
Tau2 = 0.19, I2 = 28.2%, p = 0.46
Late treatment 35%
0.65 [0.22-1.98]
8/227
11/228
35% improvement Sokhela (RCT) 66%
0.34 [0.01-8.41]
0/240
1/265
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.52
Prophylaxis 66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement All studies 28%
0.72 [0.31-1.70]
9/651
12/688
28% improvement 4 nitazoxanide COVID-19 RCT mortality results c19 early.org/n Dec 2022Tau2 = 0.00, I2 = 0.0%, p = 0.46
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI] Treatment Control Cadegiani 88%
0.12 [0.01-2.52]
death
0/357
2/137
Elalfy 87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT2
Rossignol (DB RCT) -206%
3.06 [0.13-74.6]
death
1/184
0/195
Medhat (RCT) 56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Chandiwana (RCT) -13%
1.13 [0.23-5.46]
progression
37 (n)
39 (n)
CT2
Tau2 = 0.85, I2 = 66.6%, p = 0.16
Early treatment 52%
0.48 [0.17-1.34]
10/911
46/693
52% improvement Blum (DB RCT) 67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI] Treatment Control Calderón 68%
0.32 [0.04-2.49]
death
1/17
5/27
OT1
Rocco (DB RCT) -5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau2 = 0.00, I2 = 0.0%, p = 0.23
Late treatment 40%
0.60 [0.26-1.39]
9/244
16/255
40% improvement Sokhela (RCT) 66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.52
Prophylaxis 66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement All studies 54%
0.46 [0.23-0.93]
19/1,395
63/1,213
54% improvement 10 nitazoxanide COVID-19 peer reviewed trials c19 early.org/n Dec 2022Tau2 = 0.52, I2 = 51.7%, p = 0.03
Effect extraction pre-specified (most serious outcome) 1 OT: comparison with other treatment 2 CT: study uses combined treatment Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI] Treatment Control Rocco (RCT) -2%
1.02 [0.30-3.47]
hosp.
5/194
5/198
Rocco (RCT) -16%
1.16 [0.84-1.59]
no recov.
59/194
52/198
Rocco (RCT) 12%
0.88 [0.80-0.96]
viral+
194 (n)
198 (n)
Rocco (RCT) 14%
0.86 [0.77-0.96]
viral+
136/194
162/198
Cadegiani 88%
0.12 [0.01-2.52]
death
0/357
2/137
Cadegiani 97%
0.03 [0.00-0.51]
ventilation
0/357
9/137
Cadegiani 99%
0.01 [0.00-0.17]
hosp.
0/357
27/137
Elalfy 87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT2
Elalfy 58%
0.42 [0.31-0.56]
viral+
26/62
51/51
CT2
Silva (SB RCT) 26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Silva (SB RCT) 38%
0.62 [0.36-1.05]
viral+
12/23
11/13
Rossignol (DB RCT) -206%
3.06 [0.13-74.6]
death
1/184
0/195
Rossignol (DB RCT) 79%
0.21 [0.02-1.80]
hosp.
1/184
5/195
Rossignol (DB RCT) 85%
0.15 [0.02-1.22]
severe case
1/184
7/195
Rossignol (DB RCT) 84%
0.16 [0.02-1.29]
severe case
1/112
7/126
Rossignol (DB RCT) -7%
1.07 [0.46-2.49]
recov. time
184 (n)
195 (n)
ANTICOV (RCT) -188%
2.88 [1.05-7.85]
progression
15/462
5/443
OT1 CT2
Medhat (RCT) 56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Chandiwana (RCT) -13%
1.13 [0.23-5.46]
progression
37 (n)
39 (n)
CT2
Chandiwana (RCT) -23%
1.23 [0.73-2.08]
recov. time
37 (n)
39 (n)
CT2
Chandiwana (RCT) -67%
1.67 [0.85-3.23]
viral+
27/37
25/38
CT2
Blum (DB RCT) 67%
0.33 [0.07-1.50]
death
2/25
6/25
Blum (DB RCT) 62%
0.38 [0.11-1.25]
ventilation
3/25
8/25
Blum (DB RCT) 56%
0.44 [0.22-0.89]
hosp. time
25 (n)
25 (n)
Blum (DB RCT) 90%
0.10 [0.01-1.78]
viral+
0/23
4/19
Calderón 68%
0.32 [0.04-2.49]
death
1/17
5/27
OT1
Calderón 87%
0.13 [0.01-2.33]
ventilation
0/17
4/27
OT1
Calderón 59%
0.41 [0.25-0.59]
ICU
0/17
16/27
OT1
Calderón 52%
0.48 [0.29-0.82]
hosp. time
17 (n)
27 (n)
OT1
Fowotade (RCT) -11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT2
Fowotade (RCT) -87%
1.87 [0.88-3.98]
no recov.
31 (n)
26 (n)
CT2
Fowotade (RCT) 5%
0.95 [0.34-2.64]
viral load
31 (n)
26 (n)
CT2
Rocco (DB RCT) -5%
1.05 [0.30-3.50]
death
6/202
5/203
Rocco (DB RCT) 31%
0.69 [0.40-1.17]
ICU
20/202
30/203
Rocco (DB RCT) 40%
0.60 [0.35-1.02]
oxygen
22/202
33/203
Rocco (DB RCT) 64%
0.36 [0.29-0.45]
no improv.
202 (n)
203 (n)
Rocco (DB RCT) 34%
0.66 [0.38-1.15]
no improv.
202 (n)
203 (n)
Rocco (DB RCT) 27%
0.73 [0.58-0.90]
no disch.
202 (n)
203 (n)
Rocco (DB RCT) 8%
0.92 [0.55-1.52]
no disch.
202 (n)
203 (n)
Sokhela (RCT) 66%
0.34 [0.01-8.41]
death
0/240
1/265
Sokhela (RCT) 79%
0.21 [0.01-4.31]
hosp.
0/240
2/265
Sokhela (RCT) 17%
0.83 [0.50-1.40]
symp. case
23/240
37/265
Sokhela (RCT) -21%
1.21 [0.29-1.58]
cases
23/240
37/265
Nitazoxanide COVID-19 outcomes c19 early.org/n Dec 20221 OT: comparison with other treatment 2 CT: study uses combined treatment Favors nitazoxanide
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
